Loading institutional data...
Loading institutional data...
Held by 311 of 5,944 reporting institutions (94th percentile) — extremely crowded.
Data as of Q1 2026
Loading snapshot...
Loading financials...
Loading valuation...
Loading quality & risk...
Loading dividends & returns...
Loading capital allocation...
Loading debt & leverage...
Loading performance...
Loading peer comparison...
Loading ownership map...
Loading crowding analysis...
Loading conviction analysis...
Loading buy/sell flow...
Loading ownership trends...
Loading top holders...
Loading top holders...
Top 40 institutional holders — bubble size is position value, color is the move since last quarter. Hover any holder for detail.
Drag any bubble to rearrange · size = dollar value of the position
Total shares institutions bought (green) vs sold (red) each quarter across all holders.
Inferred from quarter-over-quarter change in each fund's 13F position (new stakes count as buys, exits as sells). Not tick-level trades.
Solve the discounted cash flow backwards, then stress-test the assumptions.
To be worth $13.48 today, the market must believe free cash flow compounds 10.1%/yr for a decade (off $231M normalized FCF).
The market's 10.1% is more optimistic than its 9-yr track record.
2-stage DCF · 0.14B shares · net debt $3.6B
mean 537.2% · volatility σ 1645% · implied rate exceeded in 4/9 yrs
Central path = implied 10.1%/yr growth; shaded band = ±1σ (1645%) of this company's historical FCF volatility, widening with time. The wider the band, the less certain the growth.
Reverse DCF: rather than guessing a fair value, we solve for the growth the current price implies, then you stress-test the assumptions. Enterprise value of the FCF stream, less net debt, ÷ shares. Educational — not a recommendation.
Is the value real, and is the business safe? Academic scores + earnings quality + solvency, from SEC filings.
Safe > 2.99 · grey 1.81–2.99 · distress < 1.81
Eight indices comparing this year to last (receivables, margins, asset quality, growth, accruals, leverage). Above −1.78 suggests possible manipulation; below −2.22 is clean.
A screen, not proof — high growth alone can raise it.
Cash-conversion data unavailable. Lower/negative accruals = higher quality (Sloan).
Coverage data unavailable; leverage falling year-over-year.
F-Score (0–9 fundamental momentum), Altman Z (distress risk), and Beneish M (earnings-manipulation screen) are academic models computed from the SEC filings. Screens and context — educational, not recommendations.
What the company returns to shareholders — and whether it's covered by cash.
The dividend exceeds free cash flow (110%) — funded from the balance sheet or debt, a red flag if it persists. Last year: $159M dividends + $0 buybacks = $159M returned on $145M FCF.
9 consecutive years of dividend increases · 8%/yr.
Yields use the latest fiscal-year dividends/buybacks over current market cap. Dividends and buybacks from the SEC cash-flow statement; payout coverage vs net income and free cash flow. Educational — not a recommendation.
How management deployed cash over 10 years — and what it earned on reinvestment.
A reinvestment story — most cash went back into growth rather than to shareholders.
Reinvestment has been productive — operating income grew well per dollar put in. Current ROIC on all capital: -22%. Rough measure (includes maintenance capex).
Cash uses aggregated from the SEC cash-flow statement over 10 fiscal years. "Return on reinvestment" is a rough proxy — operating-income change ÷ cumulative CapEx + M&A — and includes maintenance capex. Educational — not a recommendation.
How much the company owes, how it's trended, and how comfortably it's serviced.
$37M of principal comes due within a year. Scheduled principal only (excludes interest & revolver draws). As of 2025-12-31 (10-K).
Green ≤ 1.5× · amber ≤ 3× · red > 3× (leverage relative to cash earnings).
Interest expense isn't separately reported — often netted into “other income (expense), net.”
Cash vs short-term debt unavailable.
Mostly long-term debt (balance-sheet current vs non-current split). See the maturity ladder above for the year-by-year repayment schedule.
Debt, cash, interest and equity from the SEC balance sheet & income statement. Effective rate = interest ÷ average debt. Maturity ladder from the SEC long-term-debt repayment schedule. Educational — not a recommendation.
EOD close · as of 2026-09-17
How a revenue dollar becomes profit — FY2025
Each value shows its share of revenue below it (common-size).
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $4.25B 100.0% | $4.37B 100.0% | $4.66B 100.0% | $4.45B 100.0% | $4.14B 100.0% | $4.09B 100.0% | $3.87B 100.0% | $4.73B 100.0% | $4.95B 100.0% | $5.28B 100.0% |
| Cost of Revenue | $2.76B 64.9% | $2.83B 64.7% | $2.98B 63.9% | $3.00B 67.3% | $2.72B 65.8% | $2.59B 63.4% | $2.44B 63.0% | $2.90B 61.3% | $2.97B 60.0% | $3.23B 61.1% |
| Gross Profit | $1.49B 35.1% | $1.54B 35.3% | $1.68B 36.1% | $1.46B 32.7% | $1.42B 34.2% | $1.49B 36.6% | $1.43B 37.0% | $1.83B 38.7% | $1.98B 40.0% | $2.05B 38.9% |
| Research & Development | $95.4M 2.2% | $112.2M 2.6% | $122.5M 2.6% | $123.1M 2.8% | $122.0M 2.9% | $121.7M 3.0% | $119.2M 3.1% | $218.6M 4.6% | $167.7M 3.4% | $184.0M 3.5% |
| Selling, General & Admin | $435.9M 10.2% | $468.0M 10.7% | $522.3M 11.2% | $512.3M 11.5% | $482.0M 11.6% | $478.5M 11.7% | $476.5M 12.3% | $435.9M 9.2% | $461.1M 9.3% | $452.2M 8.6% |
| Total Operating Expenses | $2.62B 61.5% | $1.43B 32.7% | $1.53B 32.8% | $1.38B 30.9% | $1.01B 24.3% | $1.23B 30.1% | $1.26B 32.5% | $1.59B 33.7% | $1.38B 27.9% | $4.05B 76.7% |
| Operating Income | -$1.12B -26.4% | $112.9M 2.6% | $151.9M 3.3% | $78.9M 1.8% | $410.4M 9.9% | $265.2M 6.5% | $174.7M 4.5% | $236.5M 5.0% | $598.2M 12.1% | -$2.00B -37.9% |
| Other Income (Expense), net | -$13.2M -0.3% | $900K 0.0% | $10.4M 0.2% | -$53.1M -1.2% | -$26.7M -0.6% | -$16.3M -0.4% | $68.9M 1.8% | -$6.1M -0.1% | $10.1M 0.2% | -$22.7M -0.4% |
| Pretax Income | -$1.30B -30.5% | -$80.7M -1.8% | -$8.3M -0.2% | -$139.1M -3.1% | $258.7M 6.3% | — | — | $290.6M 6.1% | $280.1M 5.7% | -$4.85B -91.8% |
| Income Tax Expense | $104.4M 2.5% | $80.0M 1.8% | -$3.9M -0.1% | -$8.2M -0.2% | $389.6M 9.4% | -$38.3M -0.9% | -$10.7M -0.3% | $159.6M 3.4% | $160.5M 3.2% | -$835.5M -15.8% |
| Net Income | -$1.43B -33.5% | -$171.8M -3.9% | -$12.7M -0.3% | -$140.6M -3.2% | -$68.9M -1.7% | -$162.6M -4.0% | $146.1M 3.8% | $131.0M 2.8% | $119.6M 2.4% | -$4.01B -76.0% |
| Per Share | ||||||||||
| EPS (Basic) | $-10.29 | $-1.25 | $-0.09 | $-1.04 | $-0.52 | $-1.20 | $1.07 | $0.95 | $0.84 | $-28.01 |
| EPS (Diluted) | $-10.29 | $-1.25 | $-0.09 | $-1.04 | $-0.52 | $-1.19 | $1.07 | $0.95 | $0.84 | $-28.01 |
| Weighted Avg Shares (Basic) | 138.5M | 137.4M | 135.3M | 134.5M | 133.6M | 136.1M | 136.0M | 137.8M | 142.3M | 143.3M |
| Weighted Avg Shares (Diluted) | 138.5M | 137.4M | 135.3M | 134.5M | 133.6M | 137.2M | 136.5M | 138.3M | 142.6M | 143.3M |
Source: SEC EDGAR XBRL filings (annual, fiscal year). Quarterly flow items are derived from cumulative filings; balance-sheet figures are as-of each period end. Ratios and margins are computed, not reported.
EOD close · as of 2026-09-17
No standout strengths flagged.
Where each multiple sits in its own 11-yr range · 9th pct blended
Dot = today · shaded = middle 50% · line = median. Lower percentile = cheaper vs its own 11-yr history.
Is the profit real, and how strong is the balance sheet?
FY2025 · every deduction from revenue to net income
DuPont — the three levers
Watch the leverage lever — a chunk of ROE comes from the balance sheet.
What the company owes vs. what it holds
Year-by-year maturities aren't in SEC companyfacts (footnote-only), so this shows the debt/cash structure and net leverage instead.
Latest year: profit growth vs revenue growth
High operating leverage: profit moved 397.7× as fast as sales — great in an upturn, painful in a downturn.
Each line as % of revenue — the trend in color
| % of revenue | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Cost of Revenue | 61.3 | 63.0 | 63.4 | 65.8 | 67.3 | 63.9 | 64.7 | 64.9 |
| Gross Profit | 38.7 | 37.0 | 36.6 | 34.2 | 32.7 | 36.1 | 35.3 | 35.1 |
| R&D | 4.6 | 3.1 | 3.0 | 2.9 | 2.8 | 2.6 | 2.6 | 2.2 |
| SG&A | 9.2 | 12.3 | 11.7 | 11.6 | 11.5 | 11.2 | 10.7 | 10.2 |
| Operating Income | 5.0 | 4.5 | 6.5 | 9.9 | 1.8 | 3.3 | 2.6 | -26.4 |
| Income Tax | 3.4 | -0.3 | -0.9 | 9.4 | -0.2 | -0.1 | 1.8 | 2.5 |
| Net Income | 2.8 | 3.8 | -4.0 | -1.7 | -3.2 | -0.3 | -3.9 | -33.5 |
Green = margin-favorable vs the row's own range · red = unfavorable.
The metrics that matter, over time
A 30-second read on PRGO: price, valuation, headline fundamentals, and an auto-generated scorecard from SEC filings. Flags are rule-based signals, not recommendations.
Total return (dividends reinvested) vs the market, from quarter-end prices.
Above 0 = ahead of the S&P 500 since the window start; below 0 = behind. Rising means it's pulling ahead.
How far the stock fell below its prior peak. Deeper, longer drawdowns = a rougher ride to the same return.
Quarter-end, dividend-adjusted (total return). Beta & volatility from quarterly returns (annualized). Benchmark is the S&P 500 (SPY total return). Annual returns compound the quarters ending in each calendar year; the first and last years in a window may be partial. Past performance doesn't predict future results.
Ranked against 1085 sector peers with collected financials. Valuation from latest close × latest fiscal-year fundamentals; 13F conviction as of 2026-03-31.
Percentile is “goodness” within the peer set (100 = best). For valuation and leverage that means cheaper / less-levered ranks higher.
| Company | Mkt cap ▼ | P/E | EV/EBITDA | P/S | Rev gr | Gross | Net | ROE | ROIC | Net D/EBITDA | 13F |
|---|---|---|---|---|---|---|---|---|---|---|---|
| BCAX | $1.20T | — | — | — | — | — | — | -34.4% | -34.4% | — | 143 |
| LLY | $1.02T | 49.6× | — | 15.7× | 44.7% | 83.0% | 31.7% | 77.8% | 29.9% | — | 4,193 |
| AKTX | $916.2B | — | — | — | — | — | — | -61.1% | -61.1% | — | 1 |
| JNJ | $643.4B | 24.2× | — | 6.8× | 6.0% | 67.9% | 28.5% | 32.9% | 20.7% | — | 4,451 |
| ABBV | $464.4B | 111.2× | 33.2× | 7.6× | 8.6% | 70.2% | 6.9% | -129% | 6.6% | 4.2× | 3,895 |
| MRK | $362.6B | 19.9× | — | 5.6× | 1.3% | 74.8% | 28.1% | 34.7% | 17.9% | — | 3,594 |
| UNH | $340.0B | 28.4× | 19.7× | 0.8× | 11.8% | 88.7% | 2.7% | 12.0% | 6.8% | 3.9× | 2,891 |
| AZN | $252.6B | — | — | — | — | — | — | — | — | — | 1,248 |
| TMO | $244.5B | 36.5× | 31.5× | 5.5× | 3.9% | — | 15.0% | 12.6% | 7.0% | 4.9× | 2,481 |
| AMGN | $202.8B | 26.4× | 17.4× | 5.5× | 10.0% | 67.2% | 21.0% | 89.1% | 12.2% | 3.8× | 3,014 |
| GILD | $183.3B | 21.8× | 20.0× | 6.2× | 2.4% | 78.8% | 28.9% | 37.5% | 17.9% | 2.4× | 2,218 |
| ABT | $178.2B | 27.5× | 19.3× | 4.0× | 5.7% | 56.4% | 14.7% | 12.5% | 10.0% | 1.4× | 2,964 |
| PFE | $156.1B | 20.2× | — | 2.5× | -1.6% | 74.3% | 12.4% | 9.0% | 5.1% | — | 2,838 |
| DHR | $147.3B | 41.3× | 30.5× | 6.0× | 2.9% | 59.1% | 14.7% | 6.9% | 5.1% | 3.4× | 2,083 |
| ISRG | $135.8B | 48.6× | 37.3× | 13.5× | 20.5% | 66.0% | 28.4% | 16.0% | 16.0% | — | 2,190 |
| VRTX | $130.4B | 33.5× | 28.6× | 10.9× | 8.9% | 86.2% | 32.9% | 21.2% | 21.2% | — | 1,609 |
| BMY | $129.4B | 18.4× | — | 2.7× | -0.2% | 71.1% | 14.6% | 38.2% | 11.1% | — | 2,431 |
| MDT | $118.5B | 24.8× | 12.6× | 3.3× | 8.4% | 65.0% | 13.2% | 9.7% | 9.4% | 0.2× | 2,114 |
| LGVN | $117.4B | — | — | 97924.4× | -49.9% | 67.0% | -1894% | -400% | -400% | — | 31 |
| CVS | $116.6B | 66.0× | 11.7× | 0.3× | 7.8% | 45.0% | 0.4% | 2.4% | 2.4% | 0.0× | 1,795 |
| SYK | $108.8B | 33.9× | 18.7× | 4.3× | 11.2% | 64.0% | 12.9% | 14.5% | 8.5% | 2.5× | 2,196 |
| MCK | $103.4B | 23.1× | 16.3× | 0.3× | 12.4% | 3.6% | 1.2% | -219% | 109% | 1.0× | 1,946 |
| HCA | $96.7B | 15.2× | — | 1.3× | 7.1% | — | 9.0% | -113% | 16.8% | — | 1,346 |
| ELV | $91.1B | 16.4× | 15.4× | 0.5× | 12.5% | 89.4% | 2.8% | 12.9% | 7.6% | 4.2× | 1,397 |
| REGN | $81.0B | 18.7× | 19.4× | 5.7× | 1.0% | — | 31.4% | 14.4% | 13.6% | 0.5× | 1,336 |
| PRGO | $1.9B | — | — | 0.4× | -2.8% | 35.1% | -33.5% | -48.6% | -21.7% | -4.6× | 311 |
Peers = companies sharing PRGO's sector (Healthcare) with collected SEC financials. Multiples use the most recent end-of-day close and latest fiscal-year fundamentals (trailing, not forward). Missing cells mean the peer never reported that line item, has no collected price, or has a non-positive denominator. Not investment advice.